Summary
Agilent Technologies, Inc. reported a net revenue of $1.028 billion for the three months ended January 31, 2016, which was flat compared to the prior year period. Despite a 2% revenue decline in Products, Services and other revenue increased by 7% to $233 million. The company saw mixed segment performance, with Life Sciences and Applied Markets revenue down 4% and Diagnostics and Genomics up 7%, while Agilent CrossLab grew 4%. Net income from continuing operations significantly increased by 32% to $123 million, translating to diluted EPS of $0.37, up from $0.19 in the prior year. This improvement was driven by higher gross and operating margins, aided by cost controls and a pension curtailment gain, along with reduced R&D expenses. Financially, Agilent maintained a strong liquidity position with $1.931 billion in cash and cash equivalents. The company generated $104 million in cash from operations, a substantial improvement from the $20 million used in the prior year. Agilent continued its capital return strategy by repurchasing $200 million of its stock and paying $38 million in dividends during the quarter. The acquisition of Seahorse Bioscience for $242 million was completed, adding to the company's strategic investments and goodwill.
Financial Highlights
57 data points| Revenue | $1.03B |
| Cost of Revenue | $491.00M |
| Gross Profit | $537.00M |
| R&D Expenses | $78.00M |
| SG&A Expenses | $304.00M |
| Operating Expenses | $873.00M |
| Operating Income | $155.00M |
| Interest Expense | $18.00M |
| Net Income | $123.00M |
| EPS (Basic) | $0.37 |
| EPS (Diluted) | $0.36 |
| Shares Outstanding (Basic) | 329.00M |
| Shares Outstanding (Diluted) | 332.00M |
Key Highlights
- 1Net revenue remained stable at $1.028 billion, with a 7% increase in Services and other revenue offsetting a 2% decrease in Products revenue.
- 2Net income from continuing operations surged by 32% to $123 million, resulting in diluted EPS of $0.37, a significant improvement from $0.19 in the prior year.
- 3Operating margin improved by 400 basis points to 15.1%, driven by higher gross margins and cost management initiatives, including a pension curtailment gain.
- 4Cash flow from operations turned positive, generating $104 million, a substantial turnaround from the $20 million used in the prior year period.
- 5The company actively returned capital to shareholders, repurchasing $200 million in stock and paying $38 million in dividends.
- 6Agilent completed the acquisition of Seahorse Bioscience for $242 million, adding to goodwill and strategic investments.
- 7A material weakness in internal controls related to income tax accounting was identified and is being addressed, though it continues to exist.